CNPR 18TH EDITION EXAM QUESTIONS
WITH COMPLETE ANSWERS 2025.
What ccdoes ccAMA ccstand ccfor? cc- ccANSWER: ccAmerican ccMedical ccAssociation
What cckind ccof cccompanies ccare ccpharmaceutical cccompanies ccjoining ccwith ccfor cca
ccsignificant ccresearch ccadvantage? cc- ccANSWER: ccGenomic cccompanies
What ccare ccsome ccspecialties ccof ccbiotechnology cccompanies? cc- ccANSWER:
ccgeneresearch, ccgenetically-altered ccdrugs, ccand ccmolecular ccbiology.
What ccindustry ccis cchaving cca ccprofound ccimpact ccon ccmedicine? cc- ccANSWER:
ccbiotechnology
Smaller ccthan ccever ccbefore, ccwhat ccfraction ccof cchealth cccare ccare ccprescriptive ccdrug
cccosts? cc- ccANSWER: ccLess ccthat cc8% ccof cctotal cchealthcare ccin ccthis cccountry
How ccmany ccterritories ccare ccin cca ccdistrict? cc- ccANSWER: cc8-12
What ccinfluences ccthe ccnumber ccof ccdistricts ccin cca ccregion? cc- ccANSWER: ccThe ccregion's
ccpopulation
What cchas ccrueled ccthe ccrecent ccgrowth ccin ccthe ccpharmaceutical ccindustry? cc- ccANSWER:
ccPopulation ccgrowth ccand ccrecent cclife ccexpectancies
Pharmaceutical ccdevelopment ccis cca cchigh ccrisk ccundertaking ccthat ccoften ccproves
ccdisappointing. cc- ccANSWER: ccTrue
According ccto ccthe cctext, ccdepression ccis cca ccdisease ccthat ccattacks ccthe: cc- ccANSWER:
cccentral ccnervous ccsystem
ML ccstands ccfor: cc- ccANSWER: ccmilliliters
The ccacronym ccfor cceffective ccdose ccis: cc- ccANSWER: cc-ed
The ccmeaning ccof ccsubcutaneous ccis: cc- ccANSWER: ccbeneath ccouter ccskin
Outside cca ccliving ccbody: cc- ccANSWER: ccex ccvivo
Refers ccto ccmedication ccdosage, ccmeans cc"hour": cc- ccANSWER: ccH
, A ccsite ccin ccthe ccbody ccwhich ccgenerally ccresides ccon cca cccell ccsurface ccor ccwithin ccthe
cccytoplasm.
When ccstimulated ccor ccoccupied, cca ccbiological ccchange/activity cctakes ccplace: cc-
ccANSWER: ccreceptor
A ccsubstance ccthat ccenhances ccthe ccaction ccof cca ccdrug ccor ccantigen: cc- ccANSWER: ccadjuvant
The ccstudy ccof ccthe cceffects, ccboth ccbeneficial ccand cctoxic, ccof ccdrugs ccand ccchemicals ccon
ccliving cccells, cctissues, ccorganisms: cc- ccANSWER: ccpharmacology
Where ccthe cctolerance ccof ccone ccmedication ccmay ccresult ccin ccincreased cctolerance ccof
ccanother ccmedication? cc- ccANSWER: cccross cctolerance
Used ccwhen ccreferring ccto ccmedication ccdosage, ccmeans cc"as ccneeded": cc- ccANSWER:
ccPRN
The ccorigin, ccor cccause, ccof cca ccdisease ccor cca ccpatient's ccsymptoms: cc- ccANSWER: ccetiology
A ccterm ccused ccto ccrefer ccto ccdrugs ccthat ccare ccnon-biological cc(that ccis, ccchemical) ccin ccnature:
cc- ccANSWER: ccsmall ccmolecule
The_____is ccused ccto ccdetermine ccappropriate ccmedical ccreimbursement. cc- ccANSWER:
ccCoding ccsystem
SS ccis ccan ccabbreviation ccfor: cc- ccANSWER: ccsemis
Another ccname ccfor ccbiologic cccompound ccis: cc- ccANSWER: cclarge ccmolecule
IDN cc- ccANSWER: ccintegrated ccdelivery ccnetwork
internist cc- ccANSWER: cca ccphysician ccwho ccspecializes ccin ccdiagnosing ccand cctreating
ccdiseases ccand ccdisorders ccof ccthe ccinternal ccorgans ccand ccrelated ccbody ccsystems
Oral ccGlaucoma ccTherapy ccis ccclassified cc- ccANSWER: ccophthalmology cctherapy
The ccacronym ccfor ccpharmacokinetics ccis: cc- ccANSWER: ccPK
A cclow ccsupply ccof ccoxygen ccdue ccto cclow ccblood ccflow ccis: cc- ccANSWER: ccischemia
The ccsubstances cccomprising ccall ccactive ccand ccinert ccpharmaceutical ccingredients,
ccincluding ccfillers, cccolors, ccand ccother ccexcipients ccused ccto ccprepare ccdosage ccforms: cc-
ccANSWER: ccformulation
Dividing cca ccgroup ccof ccphysicians ccand ccother ccpotential ccprescribers ccfor cca cccertain
cccategory ccof ccdrugs ccbased ccon ccanticipated ccprescription ccvolume: cc- ccANSWER:
ccdeclining
WITH COMPLETE ANSWERS 2025.
What ccdoes ccAMA ccstand ccfor? cc- ccANSWER: ccAmerican ccMedical ccAssociation
What cckind ccof cccompanies ccare ccpharmaceutical cccompanies ccjoining ccwith ccfor cca
ccsignificant ccresearch ccadvantage? cc- ccANSWER: ccGenomic cccompanies
What ccare ccsome ccspecialties ccof ccbiotechnology cccompanies? cc- ccANSWER:
ccgeneresearch, ccgenetically-altered ccdrugs, ccand ccmolecular ccbiology.
What ccindustry ccis cchaving cca ccprofound ccimpact ccon ccmedicine? cc- ccANSWER:
ccbiotechnology
Smaller ccthan ccever ccbefore, ccwhat ccfraction ccof cchealth cccare ccare ccprescriptive ccdrug
cccosts? cc- ccANSWER: ccLess ccthat cc8% ccof cctotal cchealthcare ccin ccthis cccountry
How ccmany ccterritories ccare ccin cca ccdistrict? cc- ccANSWER: cc8-12
What ccinfluences ccthe ccnumber ccof ccdistricts ccin cca ccregion? cc- ccANSWER: ccThe ccregion's
ccpopulation
What cchas ccrueled ccthe ccrecent ccgrowth ccin ccthe ccpharmaceutical ccindustry? cc- ccANSWER:
ccPopulation ccgrowth ccand ccrecent cclife ccexpectancies
Pharmaceutical ccdevelopment ccis cca cchigh ccrisk ccundertaking ccthat ccoften ccproves
ccdisappointing. cc- ccANSWER: ccTrue
According ccto ccthe cctext, ccdepression ccis cca ccdisease ccthat ccattacks ccthe: cc- ccANSWER:
cccentral ccnervous ccsystem
ML ccstands ccfor: cc- ccANSWER: ccmilliliters
The ccacronym ccfor cceffective ccdose ccis: cc- ccANSWER: cc-ed
The ccmeaning ccof ccsubcutaneous ccis: cc- ccANSWER: ccbeneath ccouter ccskin
Outside cca ccliving ccbody: cc- ccANSWER: ccex ccvivo
Refers ccto ccmedication ccdosage, ccmeans cc"hour": cc- ccANSWER: ccH
, A ccsite ccin ccthe ccbody ccwhich ccgenerally ccresides ccon cca cccell ccsurface ccor ccwithin ccthe
cccytoplasm.
When ccstimulated ccor ccoccupied, cca ccbiological ccchange/activity cctakes ccplace: cc-
ccANSWER: ccreceptor
A ccsubstance ccthat ccenhances ccthe ccaction ccof cca ccdrug ccor ccantigen: cc- ccANSWER: ccadjuvant
The ccstudy ccof ccthe cceffects, ccboth ccbeneficial ccand cctoxic, ccof ccdrugs ccand ccchemicals ccon
ccliving cccells, cctissues, ccorganisms: cc- ccANSWER: ccpharmacology
Where ccthe cctolerance ccof ccone ccmedication ccmay ccresult ccin ccincreased cctolerance ccof
ccanother ccmedication? cc- ccANSWER: cccross cctolerance
Used ccwhen ccreferring ccto ccmedication ccdosage, ccmeans cc"as ccneeded": cc- ccANSWER:
ccPRN
The ccorigin, ccor cccause, ccof cca ccdisease ccor cca ccpatient's ccsymptoms: cc- ccANSWER: ccetiology
A ccterm ccused ccto ccrefer ccto ccdrugs ccthat ccare ccnon-biological cc(that ccis, ccchemical) ccin ccnature:
cc- ccANSWER: ccsmall ccmolecule
The_____is ccused ccto ccdetermine ccappropriate ccmedical ccreimbursement. cc- ccANSWER:
ccCoding ccsystem
SS ccis ccan ccabbreviation ccfor: cc- ccANSWER: ccsemis
Another ccname ccfor ccbiologic cccompound ccis: cc- ccANSWER: cclarge ccmolecule
IDN cc- ccANSWER: ccintegrated ccdelivery ccnetwork
internist cc- ccANSWER: cca ccphysician ccwho ccspecializes ccin ccdiagnosing ccand cctreating
ccdiseases ccand ccdisorders ccof ccthe ccinternal ccorgans ccand ccrelated ccbody ccsystems
Oral ccGlaucoma ccTherapy ccis ccclassified cc- ccANSWER: ccophthalmology cctherapy
The ccacronym ccfor ccpharmacokinetics ccis: cc- ccANSWER: ccPK
A cclow ccsupply ccof ccoxygen ccdue ccto cclow ccblood ccflow ccis: cc- ccANSWER: ccischemia
The ccsubstances cccomprising ccall ccactive ccand ccinert ccpharmaceutical ccingredients,
ccincluding ccfillers, cccolors, ccand ccother ccexcipients ccused ccto ccprepare ccdosage ccforms: cc-
ccANSWER: ccformulation
Dividing cca ccgroup ccof ccphysicians ccand ccother ccpotential ccprescribers ccfor cca cccertain
cccategory ccof ccdrugs ccbased ccon ccanticipated ccprescription ccvolume: cc- ccANSWER:
ccdeclining
